文献速递临床试验与 GCP真实世界研究与卫生经济

ComPAS试验:急性营养不良联合治疗模式的经济学评价研究方案

The "ComPAS Trial" combined treatment model for acute malnutrition: study protocol for the economic evaluation.
PubMed 文献 · Trials · 2018-04-24

本文为ComPAS试验的经济学评价方案。ComPAS试验是在南苏丹和肯尼亚开展的整群随机对照非劣效性试验,比较治疗无并发症急性营养不良的新型联合方案与现行标准方案。经济学评价将从社会视角计算两种方案的总经济成本,估算联合方案的增量成本,并进行成本-后果分析;若主要和次要结局具统计学显著性,则计算增量成本-效果比。作者假设联合方案因简化物流、缩短治疗时长(尤其对中度急性营养不良)和减少即食治疗食品剂量而具成本效果。

要点

  • ComPAS试验比较急性营养不良联合方案与标准方案的非劣效性。
  • 经济学评价从社会视角计算两种方案的总经济成本。
  • 假设联合方案因简化物流、缩短治疗和减少即食治疗食品剂量而具成本效果。

核心结论

  • 作者假设实施联合方案将因简化诊所级物流、缩短治疗时长(尤其对中度急性营养不良)和减少即食治疗食品剂量而具成本效果。
  • 经济学评价结果对政策制定者重要,尤其考虑到主要健康结局假设的非劣效性。

研究设计与样本

  • ComPAS试验为整群随机对照非劣效性试验,在南苏丹和肯尼亚比较治疗无并发症急性营养不良的新型联合方案与现行标准方案。
  • 经济学评价将使用会计数据、访谈和调查问卷,从社会视角计算两种方案的总经济成本。

关键数值与推荐

  • 将估算实施联合方案的增量成本,所有成本和结局以成本-后果分析呈现。
  • 若主要和次要结局具统计学显著性,将计算增量成本-效果比。

临床怎么用

  • 经济学评价结果可为政策制定者提供联合方案成本效果的信息,尤其考虑到主要健康结局假设的非劣效性。
  • 方案发表旨在促进在其他营养干预研究中纳入经济学评价,尤其针对中度急性营养不良,并提高与其他研究的可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute malnutrition is currently divided into severe (SAM) and moderate (MAM) based on level of wasting. SAM and MAM currently have separate treatment protocols and products, managed by separate international agencies. For SAM, the dose of treatment is allocated by the child's weight. A combined and simplified protocol for SAM and MAM, with a standardised dose of ready-to-use therapeutic food (RUTF), is being trialled for non-inferior recovery rates and may be more cost-effective than the current standard protocols for treating SAM and MAM. METHOD: This is the protocol for the economic evaluation of the ComPAS trial, a cluster-randomised controlled, non-inferiority trial that compares a novel combined protocol for treating uncomplicated acute malnutrition compared to the current standard protocol in South Sudan and Kenya. We will calculate the total economic costs of both protocols from a societal perspective, using accounting data, interviews and survey questionnaires. The incremental cost of implementing the combined protocol will be estimated, and all costs and outcomes will be presented as a cost-consequence analysis. Incremental cost-effectiveness ratio will be calculated for primary and secondary outcome, if statistically significant. DISCUSSION: We hypothesise that implementing the combined protocol will be cost-effective due to streamlined logistics at clinic level, reduced length of treatment, especially for MAM, and reduced dosages of RUTF. The findings of this economic evaluation will be important for policymakers, especially given the hypothesised non-inferiority of the main health outcomes. The publication of this protocol aims to improve rigour of conduct and transparency of data collection and analysis. It is also intended to promote inclusion of economic evaluation in other nutrition intervention studies, especially for MAM, and improve comparability with other studies. TRIAL REGISTRATION: ISRCTN 30393230 , date: 16/03/2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lelijveld N, Bailey J, Mayberry A, et al. The "ComPAS Trial" combined treatment model for acute malnutrition: study protocol for the economic evaluation. Trials. 2018. PMID: 29690899. doi:10.1186/s13063-018-2594-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。